$3.08
-0.00500-0.16%
At close: -
$3.13
0.041.46%
After Hours: May 1, 5:24 PM EDT
Comments
Loading...
InMed Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:INM | Benzinga
InMed Pharmaceuticals Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for InMed Pharmaceuticals Corp from these most-recent analyst ratings.
Analyst Ratings for InMed Pharmaceuticals
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
No data available to display | |||||||||
FAQ
What is the target price for InMed Pharmaceuticals (INM) stock?
There is no price target for InMed Pharmaceuticals
What is the most recent analyst rating for InMed Pharmaceuticals (INM)?
There is no analyst for InMed Pharmaceuticals
When was the last upgrade for InMed Pharmaceuticals (INM)?
There is no last upgrade for InMed Pharmaceuticals
When was the last downgrade for InMed Pharmaceuticals (INM)?
There is no last downgrade for InMed Pharmaceuticals.
When is the next analyst rating going to be posted or updated for InMed Pharmaceuticals (INM)?
There is no next analyst rating for InMed Pharmaceuticals.
Is the Analyst Rating InMed Pharmaceuticals (INM) correct?
There is no next analyst rating for InMed Pharmaceuticals.
Browse analyst ratings and price targets on all stocks.
